IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives
about
Molecular Imaging of Metabolic Reprograming in Mutant IDH CellsFrom human genome to cancer genome: the first decadeSpinal cord tumours: advances in genetics and their implications for treatmentMetabolic modulation of chromatin: implications for DNA repair and genomic integrityAdaptations of energy metabolism during cerebellar neurogenesis are co-opted in medulloblastomaThe Emergence of Pan-Cancer CIMP and Its Elusive InterpretationExome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal CellsMolecular Testing of Brain Tumor.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.Oncometabolites d- and l-2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological ConditionsMetabolic requirements for the maintenance of self-renewing stem cells.Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis.Cancer stem cells as a target population for drug discovery.Metabolic reprogramming in mutant IDH1 glioma cells.Diaphorase Coupling Protocols for Red-Shifting Dehydrogenase AssaysRadiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.Targeting cancer metabolism.Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore.Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.Characterizing DNA methylation alterations from The Cancer Genome Atlas.cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.Non-invasive in vivo assessment of IDH1 mutational status in glioma.Isocitrate dehydrogenase mutations in myeloid malignancies.Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma.The Glutamate Dehydrogenase Pathway and Its Roles in Cell and Tissue Biology in Health and Disease.Origins of aberrant DNA methylation in acute myeloid leukemia.Metabolic alteration in tumorigenesis.Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathwaysEpigenetic mechanisms of tumorigenicity manifesting in stem cells.Cancer metabolomics in basic science perspective.Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases.Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.Targeting metabolic pathways for head and neck cancers therapeutics.A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors.Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.Glioma Subclassifications and Their Clinical Significance.Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis.Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
P2860
Q26750861-4A225F02-02E0-4CC6-B75C-825B4DE2072DQ26827640-C569D60A-F0C0-4A0B-A118-DA6436EE796BQ26851596-D4E995BA-16F7-449D-9B3D-581B11A69EA2Q26861294-1C16E5FF-2A2B-47A3-86F3-9EA4BF6C1680Q27015699-0940EC68-D0EE-46F0-AA64-2D1764EA1285Q28075374-3BD885F7-04A9-4BB6-883D-7E237D0065B3Q30388270-37233262-69E4-497F-9AFC-D333CB772542Q33464532-227AC6CC-8823-4801-A2CE-FBD8133FC81EQ33729693-C2018929-B33B-4FBC-BAE7-75968A2D2959Q33823065-E962B875-564C-49C1-93D4-C66E06687162Q33874560-B2600815-48AA-4FF5-A7B8-78FEBFD20128Q33893346-B33827DD-9ACD-4C66-BBA3-BA4E27B5E4F1Q35323457-3D278F99-8EA5-43F4-AC11-523546BC79AFQ35390334-EDDEC943-13BC-4C0F-BE91-BA49FCD3A395Q35566048-BAE15464-C620-419A-9338-07DBEEDA1ECDQ35989981-7725BA90-5E84-4178-9517-EABD91AE6014Q36013362-B92D194C-AC1E-464E-B727-61E559258BBEQ36330869-1FA24466-9D31-4270-B445-34E37B0498DAQ36545839-288A774F-86ED-43EE-BF23-7EFB6E1EF0CAQ37081252-D0975953-6851-4FCF-BAF2-7888FA233511Q37410593-2F88F0EA-6D6D-4790-9AF5-5E060FDEB956Q37435393-B57B66E6-5118-44B4-939B-02DDE44C3DF7Q37537230-7AFD2960-DF9C-47EE-AEF7-C77F70E8C173Q37625630-14BBEA4E-FD6F-44EB-8710-5708A4377C72Q37662166-566E0103-5BE5-4097-A463-581D08EE17C7Q37728187-FAA83D5E-5FB3-4A6F-BB73-A62C3E3A1AEBQ38130091-7BC28724-F8D7-4D9A-9A6B-52CB2EAB78CAQ38151521-58D2728D-CA58-4E78-917F-78A182604D72Q38184665-07897033-04B7-4027-BC49-26B0AFB0727BQ38220397-AB1AAFBC-3300-4844-8DF5-B2A0C3BBD029Q38335800-60BBCA43-1744-4A4C-82E4-588571F5B784Q38351687-2D2BDB28-7917-4031-B84A-E2AC76DF774BQ38569175-7E92F0AF-642D-44B5-B650-9F7CB1E8C862Q38640439-AD85B00B-300C-4F4F-997E-D7917DDD4803Q38712122-2A6580A0-260E-4FFA-BB3C-F6FDB995A7C1Q38731795-A3652BDC-3961-4EEE-894C-92EE67D4E893Q38747746-A2CC6A9B-B0EE-4808-8310-F9EAB6659C2EQ38767308-1FEA4318-96D0-4057-8797-D5F9342B127CQ38785982-6431D8EB-DD5C-4F09-A5E7-3AAFC4CF6D8EQ38810349-6993A965-0953-485D-96FE-DCB8D22ED1AF
P2860
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives
@en
type
label
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives
@en
prefLabel
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives
@en
P2093
P2860
P1476
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives
@en
P2093
P2860
P304
P356
10.1158/1078-0432.CCR-12-1773
P407
P577
2012-10-01T00:00:00Z